来源：中华预防医学会微平台
As of June 18, COVID-19 has hit over 210 countries and regions, affected more than seven billion people around the world and claimed over 440,000 precious lives. The virus does not respect borders. Nor is race or nationality relevant in the face of the disease.
In order to support Open Science advocated by UNESCO, and to share China‘s knowledge and practices in fighting COVID-19, China Centre for International Science and Technology Exchange (CISTE) has produced a series of videos titled “China's Research on COVID-19” in cooperation with CAST UN Consultative Committee on Life Sciences and Human Health (CCLH) and CAST UN Consultative Committee on Information Technology (CCIT).
No.4: Clinical Medicine
Quality clinical treatments and drugs are crucial to reduce severe cases of COVID-19 and mortality rates.
As of June 20, Chinese scholars had registered 573 clinical trials and published 1,831 journal articles on COVID-19. The research topics of these articles include early warning indicators of severe cases, the clinical management of cases, the in vitro selection of antiviral drugs and related clinical experiments, convalescent plasma therapy and immunotherapy drugs.On this basis, China has issued a series of clinical treatment guidelines and experts’ consensus statements, including COVID-19 diagnosis and treatment plan; expert consensus statement on diagnosis and treatment of severe and critical COVID-19 cases; diagnosis, treatment and prevention of COVID-19 infection in children and the elderly; and treatment of COVID-19 with chloroquine phosphate.Wenhao Dai’s group published an article in Science, titled “Structure-based design of antiviral drug candidates targeting the SARS-CoV-2”, which reported that the group has designed and synthesized two lead compounds (11a and 11b) targeting Mpro. Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. Both compounds showed good pharmacokinetic properties in vivo, which suggests that these compounds are promising drug candidates.A study by Ivan Fan-Ngai Hung’s group published in The Lancet, titled “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial”, reported that 127 patients were recruited, of whom 86 were randomly assigned to the combination test group and 41 were assigned to the control group. They found that early triple antiviral therapy was safe and superior to lopinavir–ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19.微信名称
中国国际科技交流中心
长按二维码关注我们！
来源：cpma_wpt 中华预防医学会微平台
原文链接：http://mp.weixin.qq.com/s?__biz=MzAwNDE4Njk5MQ==&mid=2736132937&idx=1&sn=c81413371e01c2948dcbc4b1807d3e7e&chksm=bdcd05498aba8c5f7b77e4f0caa4b1650dee315617aa9c440c806dd7d1d9c6bc11103dc9731b&scene=27#wechat_redirect
版权声明：除非特别注明，本站所载内容来源于互联网、微信公众号等公开渠道，不代表本站观点，仅供参考、交流、公益传播之目的。转载的稿件版权归原作者或机构所有，如有侵权，请联系删除。
电话：（010）86409582
邮箱：kejie@scimall.org.cn
